Top Markets
#1 Official Trump Official Trump +51.60%
#2 Movement Movement +32.33%
#3 Mubarak Mubarak +26.27%
#4 Pearl Pearl +24.49%
#5 Zama Zama +24.44%
#6 Melania Meme Melania Meme +22.38%
#7 EXOD EXOD +18.93%
#8 Wrapped POL Wrapped POL +18.74%
#9 POL (ex-MATIC) POL (ex-MATIC) +18.66%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +16.92%
Coin of the day
Official Trump Official Trump
Settings
Language
ENGLISH
Currency
USD
Theme
Citius Oncology, Inc. Citius Oncology, Inc.

Citius Oncology, Inc.

CTOR
Rank in Stocks #23802
Citius Oncology, Inc. concentrates on advancing innovative, targeted... Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Share Price
$0.7426
Last synced: 2026-08-21
Market Cap
$69.05M
Change (1 day)
-2.17%
Change (1 year)
-57.57%
Country
US
Trade Citius Oncology, Inc. (CTOR)

Category

Healthcare
Revenue for Citius Oncology, Inc. (CTOR)
Revenue in Aug 2026 TTM: 0
According to Citius Oncology, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Citius Oncology, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 $79.67B -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $97.93B -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 $64.39B -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 $77.52B -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $66.40B -
US